2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
02/18/13Roche and Chiasma announce collaboration to develop and commercialize Chiasma's Octreolin®
For acromegaly and neuroendocrine tumors Basel, Switzerland, New York, USA, and Jerusalem, Israel - February 18, 2013. Roche (SIX: RO, ROG; OTCQX: RHHBY) and Chiasma (pronounced key-azma) Inc., a privately held biopharma company, announced today that they have entered into an agreement to develop and commercialize Chiasma’s proprietary product Octreolin, initially for acromegaly and subsequently for neuroendocrine tumors. Octreolin is an investigational oral form of the peptide oct... 
Printer Friendly Version

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent filings with the U.S. Securities and Exchange Commission.